BioSpace News Archive

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the BofA Securities Virtual Health Care Conference.

Editas Medicine, Inc., a leading genome editing company, reported business highlights and financial results for the first quarter of 2020.

As the COVID-19 pandemic began, our priority was to make sure that our employees were safe and that we took the necessary measures to protect our supply chain operations, which have enabled us to continue to fulfill our mission of improving people’s lives with our health care products

Bicycle Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Conference Call to be Held on Thursday, May 14, 2020 at 5:00 p.m. (EDT)

Apellis Pharmaceuticals , Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that it had entered into subscription agreements with a number of institutional investors for a private placement of $300.0 million aggregate principal amount of 3.500% convertible senior notes due 2026 (the “notes”) for an aggregate purchase price of $328.9 million. The private placement is expected to close on May

Camurus announces strong first quarter demand for Buvidal and reiterates the financial outlook for 2020 with expected revenues in the higher interval

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the company will participate in and hold investor meetings at the RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20, 2020. Conference Presentation Details: Date: Wednesday, May 20, 2020 Time:

resTORbio, Inc., a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, provided a corporate update and reported financial results for the first quarter ended March 31, 2020.

Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics and Radiopharmaceutical Therapeutics Portfolio